Marie-Agnes Dragon-Durey
Overview
Explore the profile of Marie-Agnes Dragon-Durey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
2982
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Chabannes M, Rabant M, El Sissy C, Dragon-Durey M, Vieira Martins P, Meuleman M, et al.
Am J Kidney Dis
. 2023 Apr;
82(3):279-289.
PMID: 37061020
Rationale & Objective: C3 glomerulopathy (C3GN) and atypical hemolytic uremic syndrome (aHUS) are 2 distinct rare kidney diseases caused by dysregulation of the alternative complement pathway. Patients with C3GN and...
12.
Wiatr M, Hadzhieva M, Lecerf M, Noe R, Justesen S, Lacroix-Desmazes S, et al.
Int J Mol Sci
. 2023 Feb;
24(4).
PMID: 36834827
The interaction of some human antibodies with heme results in posttranslational acquisition of binding to various self- and pathogen-derived antigens. The previous studies on this phenomenon were performed with oxidized...
13.
Charbit-Henrion F, Haas M, Chaussade S, Cellier C, Cerf-Bensussan N, Malamut G, et al.
Clin Gastroenterol Hepatol
. 2022 Aug;
21(5):1368-1371.e2.
PMID: 35944833
No abstract available.
14.
Dragon-Durey M, Bizzaro N, Senant M, Andreeva H, Bogdanos D, Bonroy C, et al.
Clin Chem Lab Med
. 2022 Jun;
60(9):1373-1383.
PMID: 35749077
Objectives: No reference data are available on repositories to measure precision of autoantibody assays. The scope of this study was to document inter- and intra-run variations of quantitative autoantibody assays...
15.
Sethi S, Dhaliwal M, Raghunathan V, Raaj H, Mahato S, Vadhera A, et al.
Pediatr Nephrol
. 2022 Feb;
37(9):2053-2055.
PMID: 35166917
No abstract available.
16.
Sethi S, Dhaliwal M, Raghunathan V, Raaj H, Mahato S, Vadhera A, et al.
Pediatr Nephrol
. 2022 Feb;
37(9):2057-2058.
PMID: 35166915
No abstract available.
17.
Raina R, Sethi S, Dragon-Durey M, Khooblall A, Sharma D, Khandelwal P, et al.
Pediatr Nephrol
. 2022 Feb;
37(7):1479-1493.
PMID: 35118546
Background And Objectives: Observing biomarkers that affect alternative pathway dysregulation components may be effective in obtaining a new and more rapid diagnostic portrayal of atypical hemolytic uremic syndrome. We have...
18.
Russick J, Foy P, Josseaume N, Meylan M, Ben Hamouda N, Kirilovsky A, et al.
Front Immunol
. 2021 Jul;
12:701273.
PMID: 34322128
SARS-CoV-2 infection leads to a highly variable clinical evolution, ranging from asymptomatic to severe disease with acute respiratory distress syndrome, requiring intensive care units (ICU) admission. The optimal management of...
19.
Daugan M, Revel M, Russick J, Dragon-Durey M, Gaboriaud C, Robe-Rybkine T, et al.
Cancer Immunol Res
. 2021 May;
9(8):891-908.
PMID: 34039653
The complement system plays a complex role in cancer. In clear cell renal cell carcinoma (ccRCC), local production of complement proteins drives tumor progression, but the mechanisms by which they...
20.
Daugan M, Revel M, Thouenon R, Dragon-Durey M, Robe-Rybkine T, Torset C, et al.
Cancer Immunol Res
. 2021 May;
9(8):909-925.
PMID: 34039652
The complement system is a powerful and druggable innate immune component of the tumor microenvironment. Nevertheless, it is challenging to elucidate the exact mechanisms by which complement affects tumor growth....